First American Trust FSB Buys 1,150 Shares of Zoetis Inc. (NYSE:ZTS)

First American Trust FSB increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 45,423 shares of the company’s stock after purchasing an additional 1,150 shares during the quarter. Zoetis accounts for 1.1% of First American Trust FSB’s holdings, making the stock its 27th biggest holding. First American Trust FSB’s holdings in Zoetis were worth $8,965,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC increased its position in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the last quarter. Evermay Wealth Management LLC grew its position in Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares during the last quarter. Worth Asset Management LLC bought a new position in Zoetis in the 1st quarter valued at $26,000. Finally, Moisand Fitzgerald Tamayo LLC grew its position in Zoetis by 105.5% in the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after acquiring an additional 96 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 2,209 shares of company stock valued at $408,453 in the last ninety days. Corporate insiders own 0.15% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Piper Sandler upped their price objective on Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research report on Tuesday, February 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Stifel Nicolaus lowered their target price on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Finally, The Goldman Sachs Group upped their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $224.88.

Zoetis Stock Down 0.1 %

Shares of NYSE ZTS traded down $0.17 during mid-day trading on Monday, reaching $149.81. 8,667,336 shares of the company were exchanged, compared to its average volume of 2,930,192. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The stock has a market cap of $68.52 billion, a price-to-earnings ratio of 29.95, a P/E/G ratio of 2.29 and a beta of 0.85. Zoetis Inc. has a 1 year low of $148.48 and a 1 year high of $201.92. The firm has a 50-day moving average of $179.92 and a 200 day moving average of $180.91.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.15 earnings per share. On average, research analysts expect that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.